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Abstract Human peripheral blood and umbilical cord blood
represent attractive sources of cells for reprogramming to in-
duced pluripotent stem cells (iPSCs). However, to date, most
of the blood-derived iPSCs were generated using either inte-
grating methods or starting from T-lymphocytes that have ge-
nomic rearrangements thus bearing uncertain consequences
when using iPSC-derived lineages for disease modeling and
cell therapies. Recently, both peripheral blood and cord blood
cells have been reprogrammed into transgene-free iPSC using
the Sendai viral vector. Here we demonstrate that peripheral
blood can be utilized for medium-throughput iPSC production
without the need to maintain cell culture prior to
reprogramming induction. Cell reprogramming can also be
accomplished with as little as 3000 previously cryopreserved
cord blood cells under feeder-free and chemically defined
Xeno-free conditions that are compliant with standard Good
Manufacturing Practice (GMP) regulations. The first iPSC
colonies appear 2–3 weeks faster in comparison to previous
reports. Notably, these peripheral blood- and cord blood-
derived iPSCs are free of detectable immunoglobulin
heavy chain (IGH) and T cell receptor (TCR) gene rear-
rangements, suggesting they did not originate from B- or
T- lymphoid cells. The iPSCs are pluripotent as evaluated
by the scorecard assay and in vitro multi lineage function-
al cell differentiation. Our data show that small volumes
of cryopreserved peripheral blood or cord blood cells can
be reprogrammed efficiently at a convenient, cost effective
and scalable way. In summary, our method expands the
reprogramming potential of limited or archived samples
either stored at blood banks or obtained from pediatric
populations that cannot easily provide large quantities of
peripheral blood or a skin biopsy.
Keywords Reprogramming . Peripheral blood . Cord
blood . Sendai viral vector . Genomic rearrangement . GMP .
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Introduction
The emergence of iPSC technology, with the capability of
iPSC to undergo unlimited self-renewal and differentiation
into any type of cell, has great potential to advance transla-
tional applications including stem cell therapies and genera-
tion of large-scale collections of lines for research. The avail-
ability of precisely generated iPSC-derived functional cells to
replace or repair damaged tissues/organs will likely affect he-
matopoietic diseases therapies, facilitate the treatment of neu-
rologic disorders, cardiovascular, liver, and retinal diseases,
and possibly diabetes [1–4]. In fact, the first clinical study of
cell-based therapy using iPSC derived from patients to treat
blindness started in September 2014 in Japan (http://www.
nature.com/news/japanese-woman-is-first-recipient-of-next-
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generation-stem-cells-1.15915). This program uses
autologous iPSC-derived retinal pigment epithelium for ther-
apy. While this mechanism theoretically alleviates many im-
munological issues owing to the fact that it is patient-specific,
it requires significant time and is very expensive, thereby
making it impractical for many conditions, especially for peo-
ple with acute disease conditions. An alternative strategy is
haplobanking of allogeneic iPSC lines that could partially
match a majority of potential patients with limited immune
suppression [5, 6]. However, finding donors that have human
leukocyte antigen (HLA) homozygosis is challenging unless
one has access to donor registries of pretested individuals/
samples. The availability of a broad type of HLA-typed cells
in peripheral blood and cord blood banks suggest that these
sources are ideal for such an effort [5, 6]. Since blood units
stored in banks are mainly for clinical use, it is important to
utilize a small portion of the sample and not compromise the
ultimate therapeutic use of the blood unit.
The identity of the cell of origin from blood that un-
dergoes transformat ion into an iPSC could also
be important. White blood cells in peripheral blood, the
nucleated cells that can be reprogrammed, contain a mix-
ture of hematopoietic stem cells (CD133+ and 34+), T cells
(CD3+), B cells (CD19+), T helper cells (CD4+), macro-
phages (CD14+), erythroblasts (CD71+), and myeloid pro-
genitor cells (CD13+). As an attractive candidate that con-
tains an intact genome for iPSC generation, CD34+ blood
progenitors have been reprogrammed into pluripotent cells
by several labs using different approaches [7–10]. Howev-
er, the use of cytokines like G-CSF mobilization is often
required to get a reasonable number of CD34+ cells into the
peripheral circulation for collection, and stored samples
may have an inadequate concentration when small volumes
are used. Thus the availability of source material limits the
broad application of using CD34+ cells to generate iPSCs.
T-lymphocytes are another broadly used blood-derived cell
source for reprogramming, even though cells need to be
activated before reprogramming induction and often have
much lower reprogramming efficiency. However, just like
B-lymphocytes, T-lymphocytes harbor a set of gene rear-
rangements that may result in skewed development of T
cells and perhaps other lineages [11], and even worse, could
develop T cell lymphomas spontaneously [12]. Alternative-
ly, expanded erythroblasts are a promising source for
reprogramming using lentivirus, Sendai virus, or Epsterin-
Barr virus (EBV)-based vector approaches [13–15]. How-
ever, the prolonged cell expansion and selection with an
erythropoiesis-stimulating environment before the
reprogramming step significantly increases the cost [16].
In addition, the use of unstandardized reagents and the in-
volvement of feeders for iPSC generation will make it chal-
lenging to comply with good manufacturing practice
(GMP) regulations for clinical grade iPSC production.
In this study, we aimed to generate gene-rearrangement-
free iPSC clones from a small volume of cryopreserved blood
cells using a gene-integration free method with GMP grade
reagents. To do this, we compared three blood cell storage
methods for their cell recovery rate and cell viability, and then
carried out a screen of cell subsets that form during peripheral
blood mononuclear cell (PBMC) expansion using a collection
of cell surface markers that are expressed by specific blood
lineage cells. Antibody mediated identification of cell subsets
allowed us to characterize separate defined subpopulations.
Two types of gene-rearrangement-free blood cells, CD13+
and CD71+, were successfully and efficiently reprogrammed.
Enriched and cloned blood-derived iPSCs were then tested for
their pluripotent potential. Gene expression analysis and func-
tional assay results did not show any substantial difference
among those iPSC lines when compared to reference embry-
onic stem cell (ESC) lines. Moreover, the described method
was adapted to a 96-well plate format, allowing for medium/
high-throughout iPSC derivation for scientific purposes and
potentially for cell therapies.
Material and Methods
Blood Cell Preparation and Storage
All human whole blood samples were obtained from New
York Blood Center, cord blood samples were obtained from
Carolinas Cord Blood Bank, with approval of the local re-
search ethics committee.
For blood cell storage test, samples of peripheral blood
were processed by three methods: 1) One volume of periph-
eral blood samples was mixed with one volume of Synth-a-
freeze (SAF, Life Technologies), the mixture was centrifuged
at 600 g for 5 min to get the cell pellet. The pellet was resus-
pended with SAF and stored in the liquid nitrogen tank for
future application; 2) peripheral whole blood samples were
added to 10 % DMSO (Sigma) and stored in the liquid
nitrogen tank; 3), peripheral blood samples were processed
using the standard, 8 mL Vacutainer Cell Processing Tubes
(BD Biosciences) according to the manufacturer’s protocol.
Briefly, the PBMC-containing upper phase was collected
and washed with PBS, centrifuged at 600 g for 15 min.
The cell pellets were resuspended with SAF, and stored in
the liquid nitrogen tank. For the peripheral blood cells
used for cell fate characterization and reprogramming ex-
periments, PBMCs were prepared by method 3. For the
cord blood samples used for reprogramming experiments,
cord blood was collected from a segment attached to the
cord unit using syringe and needle. A total of about 20 μl
cord blood samples were lysed in 1 ml of 1 × red blood
cell lysis buffer (eBioscience) for 10 min before centrifug-
ing at 600 g for 5 min. The lysis buffer was removed
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after centrifugation. The cell pellets were resuspended with
cell expansion medium and seeded into low attachment plates.
Blood Cell Reprogramming
Blood cell expansion medium contained StemPro-34 SFM
(Life Technologies) supplemented with 100 ng/ml stem cell
factor (SCF, R&D Systems), 100 ng/ml FLT3 (eBiosciences),
20 ng/ml interleukin-3 (IL3, Cell Signaling), and 20 ng/ml
interleukin-6 (IL6, Cell Signaling). Medium was changed ev-
ery day for 4 days (Day -4 to Day -1, Fig. 1a) by centrifugation
to remove the medium and replacing with fresh medium. After
4 days cell expansion (Day 0), cells were transduced by Oct4,
Sox2, Klf4, and c-Myc Sendai viral vectors (CytoTune-iPSC
2.0 Sendai Reprogramming Kit, Life Technologies) at a mul-
tiplicity of infection (MOI) of 5. The transduction was per-
formed in StemPro-34 SFM supplemented with cytokines con-
taining 4 μg/mL of Polybrene by centrifugation at 2000 RPM
for 30 min. The day after transfection (Day 1), Sendai Viruses
were removed by centrifuging the cell suspension. The cells
were resuspended with fresh StemPro-34 SFM supplemented
with cytokines for 2 days. The next day (Day 3), the cells were
then collected by centrifugation, resuspended with StemPro-34
SFM without cytokines, and seeded onto Geltrex-coated plates
at the targeted densities. The medium was refreshed every other
day. From Day 6–7, the medium was changed to customized
human ESC medium Freedom-1 (Life Technologies) with daily
medium changes. Once the ESC like TRA-1-60+ iPSC
emerged, the colonies were manually picked and replated onto
Geltrex-coated plates for expansion. For extremely small num-
ber of cord blood cell reprogramming (e.g., 3000 cells), cells
were reprogrammed using the same method as above except
using a higher MOI of 15.
iPSC Purification by CD13+, CD71+ Cell Depletion
A negative selection procedure was chosen for purification of
blood-derived iPSC. Single cell suspensions of whole
Fig. 1 Derivation of human iPSCs from human peripheral blood samples.
a Scheme for reprogramming human peripheral blood. b Live whole-well
(24-well plates) and zoomed representative images of peripheral blood at
different stages during reprogramming process. Images were taken by
Celigo software. D-3: Three days before transduction; D7: Seven days
after transduction; D 10: Ten days after transduction
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reprogramming events were first labeledwith CD71MicroBeads
(Miltenyi, #130-046-201) to allow AutoMACS depletion of
CD71+ cells. The enriched cells were next labeled with biotinyl-
ated monoclonal antibody CD13 (Miltenyi, #130-103-768),
followed by incubation with anti-biotin microbeads (Miltenyi)
according to manufacturer’s recommendations and depleted
using an AutoMACS (Miltenyi). The cell purity was confirmed
by flow cytometry.
Flow Cytometric Analysis
Cultured cells were dissociated with 0.5 mM EDTA (Life
Technologies). Single cell suspensions were collected by cen-
trifugation and suspended at 3×104 to 1×105 in 100 μL of
cold PBS containing 2 mM EDTA and 0.5 % BSA (FACS
buffer). Specifically labeled antibodies or appropriate isotype
controls were added, and cells were incubated further for
30 min. Cells were washed once and resuspended in 200 μL
of FACS buffer. To determine pluripotency of derived iPSCs,
cells were stained with CD13 (BD Biosciences, #555394;
1:100 dilution), SSEA-4 (BD Bioscience, #560219; 1:100 di-
lution), TRA 1-60 (BD Bioscience, #560173; 1:100 dilution)
and DAPI (Life Technologies; 1μg/mL). To determine the cell
fate before and after blood cell reprogramming, cell were la-
beled with PE-conjugated, FITC-conjugated, APC-
conjugated or V450 –conjugated antibodies against CD3
(BD Biosciences #555333), CD4 (BD Biosciences
#553730), CD13 (BD Biosciences #340686), CD13 (BD Bio-
sciences #558744), CD14 (BD Biosciences #553740), CD15
(BD Biosciences #561584), CD19 (BD Biosciences
#553785), CD34 (Miltenyi Biotec #130-081-002), CD45
(BD Biosciences #560368), CD71 (BD Biosciences
#551374), TRA-1-60 (BD Biosciences #560380, #563187),
and SSEA-4 (BD Bioscience, #560219, #560308). Stained
cells were analyzed on a 5 laser BD Biosciences ARIA-
IIu™ SOUCell Sorter. The resulting data were analyzed using
FlowJo software (Treestar).
Embryoid Body Formation
To form embryoid bodies (EBs), undifferentiated hiPSC were
dissociated with 0.5 mM EDTA (Life Technologies) and were
collected and resuspended in Freedom-1 medium supplement-
ed with 1 μM Thiszovivin (Stemgent). The cells were added
to low attachment 24-well plates and incubated for 24 h at
37 °C in a 5 % CO2 atmosphere to form EBs. The medium
was change to hEB medium consisting of 80 % DMEM/F12
medium, 20 % knockout serum replacement (KSR,
Invitrogen), 1 % non-essential amino acids (NEAA,
Invitrogen), 1 mM GlutaMAX (Invitrogen), 0.1 mM β-
mercaptoethanol (Sigma) and refreshed every day. After
16 days of incubation, total RNA was isolated from EBs.
The expression levels of each differentiation and pluripotent
markers were determined using Nanostring, as described
below.
Gene Expression Analysis of iPSCs
Nanostring (Nanostring Technologies) and Scorecard analysis
was performed as described [17]. iPSCs were cultured in
Freedom-1 medium before RNA isolation. To measure their
differentiation propensities, undifferentiated blood-derived
iPSC and EBs were collected and total RNA was extracted
using RNeasy plus kit (Qiagen). One hundred nanograms of
RNA was profiled on the Nanostring nCounter system
(Nanostring technologies) according to the manufacturer’s in-
structions. A custom nCounter codeset for Pluri25 covering
25 genes that evaluate cell pluripotency and a custom
nCounter codeset for 3GL covering 83 probes that monitor
differentiation were used. Lines were analyzed in biological
duplicates for each hESC reference line and iPSC line. All
data were normalized analyzed with nSolver Analysis Soft-
ware (Nanostring Technologies, USA).
Immunohistochemistry Staining
Cell lines were rinsed with 1X PBS, fixed with 4 % parafor-
maldehyde (Santa Cruz, #sc-281692) in PBS for 5 min at
room temperature. Nonspecific binding sites were blocked
by incubation with PBST (PBS supplemented with 0.1 % Tri-
ton X-100) containing 10 % donkey serum (Jackson Labs,
#017-000-1210) for 30 min at room temperature. Cells were
subsequently incubated overnight at 4 °C in PBST containing
10 % donkey serum and specific primary antibodies: 1:500
anti-Human OCT4 (Stemgent, #09-0023), 1:100 anti-human
NANOG (Cell Signaling Technologies, #4903), 1:250 anti-
human SSEA4 (Abcam, #ab16287), 1:500 anti-TRA-1-60
(Life Technologies), 1:200 anti cTnT, 1:200 anti-ACTIN,
1:200 anti-SOX1, 1:200 anti-SOX2, 1:200 anti-NESTIN,
8 ng/ml anti-SOX17, 10 ng/ml anti-ALB, 1:500 anti-Sendai
Vector (MBL, #PD029). Following a 3 times wash with PBS,
cells were incubated with one of the following secondary an-
tibodies: Alexa Fluor® 488 donkey anti-Mouse (#A-21202;
1:1000 dilution), Alexa Fluor® 555 donkey anti-goat IgG and
Alexa Fluor® 555 donkey anti-rabbit IgG (#A-21428; 1:1000
dilution). After washing 3 times with PBS, the samples were
incubated for 10min with Hoechst (1μg/ml) in PBS, followed
by a final wash in PBS. Fluorescence images were captured
with the Celigo, Nikon Eclipse TE 2000-U or Olympus BX41
fluorescent microscopes.
DNA Isolation
DNA isolation from the cell pellets was achieved using the
High Pure Template PCR Template Preparation Kit (Roche,
#11796828001) per manufacturer’s instructions with the
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following modifications: 1) cells were treated with 4 μL of
RNase (Qiagen, #19101) for 2 min while resuspended in PBS;
2) DNAwas eluted in 30 μL of water.
T-Cell and B-Cell Rearrangement Assay
PCR was used to identify clonal TCR and IG gene rear-
rangements using a commercially available method
employing multiple multiplexed PCR tubes that was origi-
nally developed as the result of a large European
BIOMED-2 collaborative study (Invivoscribe Technolo-
gies). For IGH gene detection, PCR (35 cycles of 94 °C
for 30 s, 55 °C for 30 s, and 72 °C for 1 min) was
performed using 1 U of AmpliTag Gold polymerase (Life
Etchnologies) in a 27.5 μl reaction with 100 ng of genomic
DNA and 25 μl of primer master mix. For TCRB, TCRD,
and TCRG genes detection, PCR (35 cycles of 94 °C for
45 s, 60 °C for 45 s, and 72 °C for 90 s) was performed.
All PCR started with initial denaturation at 95 °C for 7 min
and ended with final extension at 72 °C for 10 min before
holding at 4 °C. PCR products were detected on 2 % aga-
rose gels.
In Vitro Directed Differentiation Assay
The derived cells were induced to differentiation into NSC
[18, 19], cardiomyocyte [20], as well as hepatocyte-like cell
[21] as described below.
Directed NSC differentiation procedure consists of a 11-
day neural induction, as described previously [18, 19]. iPS
cells were seeded at a density of 1.5×106 per well of 6-well
plates when initializing the neural differentiation. The cultures
were then treated with dual-SMAD inhibitors, LDN193189
(100 nM) and SB421542 (10 μM), sonic hedgehog (SHH,
200 ng/mL), puromorphamine (2 μM), FGF-8b (100 ng/
mL), and CHIR 99021 (3 μM). Differentiated cells were
stained with neural stem cell markers, SOX1 (R&D,
AF3369), SOX2 (Stemgent, #09-0024) and NESTIN
(Millipore, #mab5326).
Directed differentiation of hESCs to cardiomyocytes was
achieved by temporal modulation of glycogen synthase ki-
nase 3 (GSK3) inhibition followed by Wnt inhibition as
previously described [20]. Briefly, blood reprogrammed
lines were seeded at 2.5×105 cells per well of 24-well
coated plates and maintained with mTeSR1 for 3 days.
On Day 0 of differentiation, medium was replaced with
RPMI plus B-27 without insulin (Life Technologies,
#0050129SA) plus GSK3 inhibitor CHIR99021 (Stemgent,
12 μM) for 24 h. On Day 1 of differentiation, CHIR99021
was removed and replaced with RPMI plus B-27 minus
insulin alone until Day 3. On Day 3 of differentiation,
medium was replaced with RPMI plus B-27 without insulin
plus Wnt inhibitor 2 (IWP2, Stemgent, 5 μM) for 48 h
until Day 5. On Day 5 of differentiation, IWP2 was re-
moved and replaced with RPMI plus B-27 without insulin
until Day 7. On Day 7 of differentiation, medium was
replaced with RPMI plus B-27 and subsequently main-
tained by exchanging RPMI B-27 every 3 days. Differen-
tiated cells were stained with cardiomyocyte markers,
NKX2.5 (Santa Cruz, #sc-14033), Troponin/cTnT (Bioss,
#bs-2804), and ACTIN (Sigma-Aldrich, #A7811).
Directed human hepatocyte-like cell differentiation were
first induced to definitive endoderm (DE) by treating with
STEMdiff Definitive Endoderm kit (Stem Cells Technologies,
#05110) for 5 days, followed by the treatment of 50 ng/ml
Activin A (R&D Systems) for 3 days. To induce hepatoblast
formation from DE, the cells were then cultured with serum-
free differentiation medium supplemented with 10 ng/ml
FGF10 (R&D Systems), 10 ng/ml bone morphogenetic pro-
tein 4 (BMP4, R&D Systems) for 4 days. During the hepato-
cyte commitment and maturation stage, cells were cultured
with HCM hepatocyte culture medium (Lonza) containing
50 ng/ml HGF (R&D Systems) and 20 ng/mL oncostatin M
(OSM, R&D Systems) for 7 days. Differentiated cells were
stained with hepatocyte cell markers ALB (R&D Systems,
#MAB1455), AFP (Abcam, #ab3980). Albumin (ALB) secre-
tion levels were determined by Albumin Human ELISA Kit
(Abcam, #ab108788). The ability of the hepatic-like cells to
store glycogen was calculated by Periodic acid-Schiff (PAS)
staining (Sigma, #395B).
Albumin ELISA Assay
Albumin concentrations in supernatants were detected by
ELISA assay as AbcamHuman Albumin ELISA Kit (Abcam,
#ab108788) according to the manufacturer’s instructions.
Briefly, conditioned media from undifferentiated cells and
blood-iPSC derived hepatocyte-like cells were collected at
Day 20. One hundred microliters of each standard, control,
and samples were loaded to each well and incubated for 1 h,
followed by five washes. The plate was incubated with bio-
tinylated human albumin detection antibody for 30 min,
washed five times, and incubated with SP conjugate for an-
other 30 min, washed five times, immersed in chromogen
substrate for 20 min. After adding stop solution, the plate
was read at 450 nm using an absorbance reader (BioTek
ELx800). The concentration of human albuminwas calculated
according to a four-parameter logistic equation.
Periodic Acid-Schiff (PAS) Staining
PSA staining was performed using Periodic acid-Schiff Kit
(Sigma, #395B) according to manufacturer’s instructions with
minor adaptations. Briefly, cells were fixed in 4 % formalde-
hyde for 1–2 min, washed with PBS, stained for 5 min with
1 % periodic acid, and washed with distilled water prior to
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incubation with Schiff’s reagent for 15 min. After washing
three times with water, cells were counterstained for 90 s with
hematoxylin solution, and washed again three times with wa-
ter prior to microscopic examination and imaging.
Karyotyping and G-banding
GTG-banding chromosome analysis was carried out in Cell
Line Genetics Laboratories. Standard DNA spectral
karyotyping procedures were followed and a HiSKY Com-
plete Cytogenetic System was used (Applied Spectral Imag-
ing, Vista, CA). Data were interpreted by a certified cytoge-
netic technologist.
Results
Blood Storage and PBMC Preparation
Given the frequent instances in which blood might not be
processed immediately, a question has arisen as to how best
to store a good quality blood sample. Three methods have
been tested to store four blood samples by evaluating the cell
viability following cryopreservation and thawing. Since cell
viability counting is a highly subjective assay, with significant
variation in results among different personnel when analyzing
the same cell sample, a robotic system Countess (Life Tech-
nologies) was used to assess viability using trypan blue as an
assay reagent. Method One is termed as SAF: blood samples
were mixed with one volume of SAF, and were centrifuged to
get the cell pellets. The cell pellets were resuspended with
SAF and cryopreserved in a liquid nitrogen tank; Method
Two is termed as DMSO: blood cells were cryopreserved after
mixing with 10 % cryoprotectant DMSO; Method Three is
termed as VCPT: PBMC were isolated using Vacutainer Cell
Processing Tubes (VCPT), and cryopreserved with SAF. We
observed 66.7–78.3 % cell viability in blood cells processed
by method one, 41–63.9 % cell viability in cells prepared by
method two, and 87.5–96 % cell viability in isolated PBMC
samples that were isolated by method three (Supplemental
Figure S1B). Thus, the results obtained indicate that the VCPT
method would give us the best cell viability but it requires
additional time and an aseptic environment for cell prepara-
tion. The second method leads to death of about 50 % of the
cells, however it is the fastest and most convenient way to
store blood samples if cell processing is not allowed before
cell cryopreservation. The first method could also be a fast and
convenient way to store viable whole blood samples with
limited processing.
As individuals have varying number of white blood cells,
we sought the volume range of frozen peripheral blood needed
for reprogramming. We evaluated the efficiency of PBMC
isolation using vacutainer cell preparation tubes (BD), and
used the value of PBMC yield and cell viability to determine
the volume range of cryopreserved peripheral blood needed
for iPSC generation. PBMC were isolated from eight donors
with yields varying at 0.43–4.5×106/mL with 88–98 % cell
viability (Supplemental Figure S1A).
High Efficiency of Human PBMC Reprogramming Using
a Low Attachment Plate
We used Sendai viral vector to reprogram blood cells
because it is a negative-sense RNA virus with no po-
tential for gene integration with concomitant by high
t ransduct ion eff ic iency. Curren t pro tocols for
reprogramming peripheral blood cells are based on
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life
technologies) with modifications.
In our initial experiment, PBMCs were seeded on standard
24-well plates. The cells were cultured in the presence of IL3,
IL6, SCF and FLT3 for 4 days to expand the hematopoietic
progenitors, and transfected with Sendai virus encodingOct4,
Sox2, Klf4, and cMyc. After 2 days of recovery, the transduced
blood cells were transferred onto Geltrex (Life Technologies)
coated plates and cultured without cytokines for another
4 days. At Day 7, the cells were incubated with customized
human ESC medium Freedom-1 (Life Technologies). The
first iPSC colonies appeared approximately 1 week after trans-
fection (Day 7, Fig. 1b). To determine the appropriate cell
number needed for reprogramming, we set up a cell seeding
density experiment in standard 24-well plates (25 to 200 k per
well of 24-well plates). We found although most of the cells
stayed in suspension, some cells spontaneously attached to the
culture surface during the 4-day cell expansion (for instance,
for PL#7, we observed more cells attached to the culture sur-
face from 50 k seeding well than from 25 or 100 k seeding
wells). Both the attached and suspended cells can be
reprogrammed as demonstrated by the appearance of TRA-
1-60+ colonies, though the reprogramming efficiency varies
from sample to sample (0.15–0.32 %, Fig. 2a). We observed
that initial seeding at 25–50 k per well of 24-well plates result
in a uniform distribution of TRA-1-60 positive colonies, while
there are too many colonies to distinguish if more than 100 k
cells were seeded (Fig. 2a).
In order to reduce the variation introduced by cell attach-
ment and cell loss during cell dissociation, we next studied the
applicability of mononuclear cell expansion in 96-well low
attachment plates. The results (Fig. 2b) indicate that culturing
PBMCs in low attachment did not compromise the
reprogramming efficiency (representative results of donor line
PL#10 and PL#11).
In addition to the application of Freedom-1 medium
during iPSC reprogramming, we also examined the ef-
fect of the other GMP-grade xeno-free media, Essential
E8 (Life Technologies) and E6 (Life Technologies) supplemented
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with 10 ng/ml bFGF (as the presence of TGFβ in E8
medium may inhibit early stage cellular reprogramming). As
shown in Fig. 2b, we did not observe notable differences in
reprogramming efficiency in the three medium treatments. The
established iPSC lines used in the following characterizationwere
maintained with Freedom-1 medium.
Characterization of Expanded PBMC Culture
As mononuclear cells are a heterogeneous group of nucleated
cells, incubation of mononuclear cells with a combination of
cytokines could selectively expand one or several types of
blood cells. We next asked what cell type(s) are
reprogrammed using this protocol by characterizing the cell
fates during cell expansion and reprogramming. During the 4-
day PBMC expansion period, a portion of mononuclear cells
were collected daily for characterization using flow cytometry.
At the end of the 4-day cell expansion, an 80-200–fold expan-
sion of CD71+ erythroblast, a ~1.5–fold expansion of CD13+
cell, a slight increase of CD34+ progenitors, and a decrease in
the percentage of CD14 (~12 fold decrease) were observed.
While >95 % of the cells manifested a hematopoietic cells
characteristic (CD45+), this culture condition did not expand
mature T-lymphocytes (CD3+) and B-lymphocytes (CD19+),
as indicated by decreased and low percentage of cells present
in the expanded cell culture (Fig. 3a, 0.21–0.40 % CD3+ and
0.03–0.64 % CD19+). These observations indicated that
CD13+ myeloid progenitors and/or CD71+ erythroblast cells
are dominant after 4 days of cell expansion.
Surface Marker Profile of PBMC-Derived Cell Culture
Undergoing Reprogramming
We observed that iPSC colonies appeared 7–10 days after
transfection identified by typical human ESC morphology
and expression of pluripotent cell surface marker TRA-1-
60 (Fig. 1b). Commonly used hiPSC purification strate-
gies include manual colony picking, FACS, magnetic
Fig. 2 Seeding density and attachment effect on peripheral blood
reprogramming. a, upper panel: representative live whole-well TRA-1-
60 images from wells of 24-well plates containing different seeding num-
ber. After 4 days cell expansion, the cell in suspension were collected for
reprogramming induction, and named as Suspended Cells; the cell at-
tached to the plate bottom were dissociated with 0.5 mM EDTA and
transfected with reprogramming factors and termed as Adherent Cells.
Images were recorded by Celigo software 10 days post reprogramming
factors transduction. Lower panel: reprogramming efficiency for each
peripheral blood samples. Efficiency was calculated based on total
TRA-1-60 colony count from both suspended cells and adherent cells
for each seeding density. b, upper panel: representative live whole-well
TRA-1-60 images from wells of 96-well plates containing different
seeding number. Three kinds of hESC medium were tested in the
reprogramming assay (Freedome-1, E8, and E6+bFGF), images were
recorded by Celigo software 10 days post reprogramming factor trans-
duction. Lower panel: reprogramming efficiency for each condition was
calculated based on the total TRA-1-60 colony count
658 Stem Cell Rev and Rep (2015) 11:652–665
bead separation on TRA-1-60 or complement depletion.
Among them, complement depletion offers the advantage
of being able to adapt to automation platforms for large-
scale production [22]. Therefore, we next sought to find
the surface markers that allow the purification of iPSC
from the refractory bulk populations by depleting the
un-reprogrammed cells. Four independent reprogramming
cultures (RC_A, RC_B, RC_C, RC_D) were picked ran-
domly on day 14 after induction of reprogramming. The
bulk populations of each reprogramming culture were dis-
sociated and subjected to FACS analysis using blood
sublineages and common pluripotency markers.
We found significant molecular changes that indicate
the commitment to the iPSC cell fate: the appearance of
pluripotent cell surface markers SSEA4+ (75.1–95.8 %)
and TRA-1-60+ (45.5–63.6 %) was paralleled by a signif-
icant decrease in the expression of the pan-leukocyte re-
ceptor CD45+ (before reprogramming 89.4–92.9 % versus
after reprogramming 0.10–5.3 %), and a decrease in the
expression of CD13 (before reprogramming 58.3–69.1 %
versus after reprogramming 9.6–20.3 %) (Fig. 3a and b).
We also observed a certain degree of heterogeneity in the
reprogramming populations: approximately half of the
SSEA4+ cells have expression of TRA-1-60, suggesting
they are at a more mature iPSC stage as early as at 14 days
post induction of reprogramming (Fig. 3c). The finding
that these SSEA4+TRA-1-60+ cells also express CD71
and/or CD13 (Supplemental Figure 2) indicates their
CD71+ or CD13+ origins. A portion of CD71+ cells be-
comes double positive for TRA-1-60 (Fig. 3d), further
suggesting that cells are CD71+ origin and in the transi-
tion stage of converting from CD71+ to iPSCs.
We next purified iPSC by depleting un-reprogrammed
CD71+ and CD13+ cells using anti-CD71 magnetic
beads and anti-CD13-Biotin microbeads (Miltenyi). The
purified cells were seeded on Geltrex-coated plates and
Fig. 3 Cell fate characterization. a, Expression of blood sublineage cell
surface markers in PBMC during 4-day cell expansion. b, Expression of
blood sublineages and common pluripotencymarkers in four independent
reprogramming cultures RC_A, RC_B, RC_C, RC_D, collected on day
14 after reprogramming induction. c, Flow cytometry analysis of SSEA4
and TRA-1-60 expression on representative reprogramming culture RC_
B. d, Flow cytometry analysis of CD71 and TRA-1-60 expression on
representative reprogramming culture RC_B. e, Purified iPSCs express
pluripotencymarkers OCT4 and TRA-1-60. DAPI services as a control, f,
Flow cytometry analysis of CD71 and CD13 expression on purified
iPSCs
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subsequently cultured for 6 days to re-establish iPSC
colonies. Immunohistochemistry results showed that the-
se cells express pluripotent markers OCT4 and TRA-1-
60 (Fig. 3e) suggesting their pluripotency, and FACS
analysis data demonstrate that the cells were completely
eliminated the CD13 and CD71 population in the puri-
fied iPSCs (Fig. 3f).
BloodDerived iPSCs are Free fromGeneRearrangements
and Transgenes
Since iPSCs carrying pre-existing gene rearrangement
may have uncertain functional consequences [12, 23],
we used PCR to detect clonal IGH and TCR gene rear-
rangements in iPSCs to determine if they were derived
from B- or T- lymphocytes. As shown in Fig. 4, where-
as the clonal control and parental whole blood cells
showed bands reflecting the presence of gene rearrange-
ments, all tested iPSC lines did not show bands in the
valid size range for TCRB_Vβ + Jβ, Vβ + Jβ2, Dβ +
Jβ (Fig. 4a), TCRG (Fig. 4c), TCRD (Fig. 4d), and
IGH gene rearrangements (Fig. 4b), indicating they were
derived from non-B, non-T cells. This could be ex-
plained by the selective cell growth of CD13+ and
CD71+ cells with the cell expansion cocktail (Fig. 3a).
In addition, the generation of iPSC free of integrated
reprogramming factor genes is essential to reduce differentia-
tion biases and artificial phenotype [24]. Immunochemistry
staining with anti-Sendai antibody was negative for Sendai
virus vector in all test colonies that were obtained at passage
5 (Fig. 5g), confirmed that Sendai virus vector were diluted
out during the proliferation, and no transgene were carried in
the iPSCs.
PBMC-Derived iPSC Characterization
iPSC colonies were expanded into stable iPSC lines that
displayed the morphology characteristic of human ESCs,
stained positive for the pluripotency markers OCT4, SOX2,
SSEA4 and NANOG (Fig. 5a), and had a normal karyotype
(Fig. 5b). Nanostring Pluri25 analyses of pluripotent genes
Pou5f, Zfp42, Sox2, Klf4, Nanog, Lin28, and Myc confirmed
pluripotency (Fig. 5e). To assess the in vitro differentiation
capacity of the iPSC lines, the cells were differentiated into
EBs. Immunohistochemistry staining for spontaneous differ-
entiation revealed that protein for all three germ layers includ-
ing ectoderm (Tuj1), mesoderm (SMA) and endoderm (ALB)
were present indicative of pluripotent status (Fig. 5b). Score-
card assay of ectodermal, mesodermal, and endodermal
markers demonstrated that all three germ layer markers were
Fig. 4 TCR and IGH rearrangement analysis in PBMC and CB iPSCs. a,
PCR analysis of TCRB rearrangements. b, PCR analysis of IGH
rearrangements. c, PCR analysis of TCRG rearrangements. d, PCR
analysis of TCRD rearrangements. e, Specimen control. IVS-0000:
polyclonal control DNA; IVS-0004, IVS-0021, IVS-0030: clonal
control DNA; H2O: no template control; Buffy coat: genomic DNA
from buffy coat PL#10
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expressed at a level similar to the reference human ESC lines
(Fig. 5f).
High Reprogramming Efficiency for Umbilical Cord
Blood (UCB)
The same strategy was applied to reprogram mononuclear
cells of UCB from a child enrolled in the Duke Task Force
for Neonatal Genomics (TFNG), a whole exome sequencing
and functional testing program aiming to accelerate gene dis-
covery and diagnosis in young childrenwith suspected genetic
disease. Due to the limitation of valuable cell resource, we
collected 3000 cells from a thawed segment of a
cyropreserved cord blood unit, and applied MOI of 15 to
induce reprogramming. As shown in the Fig. 5c, we obtain-
ed approximately 52 clones, with a reprogramming efficien-
cy at 1.73 %. We manually picked six colonies to establish
iPSC lines. All iPSC lines carry the causal gene mutations in
ELK3 (Fig. 5c) indicating they were derived from UCB cells
harboring the mutations. All iPSC lines displayed the typical
ESC morphology, free of gene rearrangements (Fig. 4).
Three derived iPSC lines maintained a normal karyotype,
and were free of Sendai Vectors (Fig. 5g). All iPSC lines
could differentiate towards three germ layers (Fig. 5d),
displaying similar gene expression patterns as hESC refer-
ence lines in both Nanostring Pluri25 and 3GL scorecard
assays (Fig. 5e and f).
Directed Differentiation of iPSCs Towards Functional
Cells from Three Germ Layers
Next, we evaluated the differentiation potential of peripheral
blood-derived iPSC (PBMC-iPSC) and cord blood-derived
iPSC (CB-iPSC) into neural s tem cel ls (NSCs) ,
cardiomyocytes, and into hepatocyte-like cells that are used
commonly for toxicity testing and predicting drug
metabolism.
We applied a multistage differentiation protocol developed
previously to promote the conversion of human iPSCs into
NSCs [18, 19] via inhibition of TGFβ and BMP signaling in
a defined cell monolayer system. The treatments resulted in
the emergence of typical NSCs that express marker proteins
such as SOX1, NESTIN, and SOX2 at a similar efficiency
across the iPSC lines (95±5.6 %) (Fig. 6a).
In vitro cardiomyocyte differentiation of iPSCs
proceeded through modulating Wnt/b-catenin signaling
[20]. We found all PBMC-iPSC and CB-iPSC lines follow-
ed a similar pattern of cardiomyocyte differentiation, could
form spontaneously contracting areas, and the contracting
myocytes were stained positively with anti-α-Actin and an-
ti-cTnT, although variation in differentiation efficiency was
observed among different iPSC lines. Testing of three
PBMC-iPSC clones revealed similar differentiation kinetics
and marker expression profiles (Fig. 6b).
In vitro hepatocyte-like cell differentiation of PBMC-iPSC
and CB-iPSC was performed as described previously [21].
The PBMC-iPSC and CB-iPSC lines were differentiated
using a step-wise, efficient approach into hepatocyte-like cells
that show cobblestone morphology, bi-nucleation, express he-
patocyte specific genes such as AFP, ALB (Fig. 6c), and ex-
hibit glycogen storage (measured by PSA staining) as well as
phenotypic characteristic of hepatocytes like albumin secre-
tion (Fig. 6d and e).
Discussion
Production of blood cell derived iPSC is currently a costly and
tedious endeavor, limited by low efficiency and slow kinetics.
Here we show blood reprogramming can be achieved within
2 weeks from cell collection to iPSC purification and can be
scaled up to 96-well plates format, thus simplifying and
streamlining the manufacturing process, and enabling the
adaption to medium/high-throughput hiPSC production.
We demonstrate that blood cells from a small tube segment
attached to a cryopreserved cord blood unit are sufficient to
generate iPSC lines without compromising their ultimate ther-
apeutic use. This is an important advance to permit access to
numerous frozen samples already stored at blood banks since
the samples are often of restricted use for research due to
limited cell numbers for therapeutic purposes. The minimal
volume of blood materials required for reprogramming varies
for each individual as the mononuclear cell density varies.
When fresh peripheral blood is obtained from normal donors,
the yields are in the range of ~0.5–4×106 mononuclear cells/
Fig. 5 Characterization of iPSCs derived from PBMC and cord blood.A subset of iPSC clones was characterized. The experiments demonstrated in the
figure provide representative examples of the results observed for iPSC clone 1, 2, 3 derived from peripheral blood donor PL#10, and iPSC clone 1, 2, 3
derived from cord donor CB1. a, PBMC derived-iPSCs show typical human ESC morphology express pluripotent markers OCT4, SOX2, SSEA4,
NANOG detected by immunochemistry. b, Representative cytogenetic analysis on G-banded metaphase cells from iPSC clone 1 exhibiting a normal
karyotype. iPSCs can form EB, spontaneously differentiate towards ectoderm (Tuj1), mesoderm (SMA), and endoderm (SMA), and endoderm (ALB). c,
Approximately 3000 cord blood cells were efficiency reprogrammed. Picked colony shows typical human ESC morphology, express plurinent cell
surface marker TRA-1-60, patient disease ELK3 gene mutations conforming the sample identity. d, Cord blood derived iPSCs can form EB efficiently,
spontaneous differentiation results show their differentiation potential towards ectoderm (NESTIN, Tuj1), mesoderm (SMA), and endoderm (AFP). e,
Pluripotent gene expression determined by quantifying RNA transcripts counts using nCounter Analysis System, error bars represent standard deriva-
tion of the mean (n=2). f, Hierarchical Cluster of EBs. g, Detection of sendal viral vector by immunohistochemistry
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mLwith a viability >95% (Supplemental Figure S1B).Mono-
nuclear cells from frozen peripheral blood would have a lower
yield due to cell damage during cryopreservation. In this
study, we tested three cryopreservation methods, and found
even freezing cells using 10 % DMSO mixed with whole
peripheral blood will have ~50 % cell viability on recovery
(Supplemental Figure S1A), thus offering a not so optimistic
but very convenient method to collect samples especially where
no applicable sterile environment exists for mononuclear pro-
cessing. We demonstrated that ~30,000 mononuclear cells can
be efficiently reprogrammed using Sendai viral vectors.
Assuming that yields of mononuclear cells from periph-
eral blood are 1×106/mL and 50 % of cells would be
lost during cell cryopreservation, approximately 60 μl of
frozen peripheral blood will be needed for iPSC gener-
ation, making the iPSC technology more broadly appli-
cable to vulnerable individuals, such as pediatric pa-
tients with severe medical challenges and unique HLA
sample segments without disturbing the blood units. For
those valuable samples with limited available cells,
reprogramming could be performed using higher MOI
Sendai viral vector to increase the efficiency.
Fig. 6 Directed differentiation of blood cell-derived iPSCs.
Representative examples of the results observed for iPSC clone 3
derived from peripheral blood donor PL#10, and iPSC clone 1 derived
from cord blood donor CB1. a, NSC differentiated from iPSCs. Cells
stained with neural stem cell specific markers SOX1, SOX2 and NEST
IN. b, Cardiomyocyte differentiated from iPSCs, cell stained with
markers α-Actinin (ACT). NKX2.5, Troponin T (TnT), and DAPI. c,
Hepatocyte-like cells differentiated from iPSC. Cells stained with
α-fetoprotein (AFP), albumin (ALB), and DAPI. d, Periodic acid-Schiff
(PAS) staining. Purple color in cells indicates glycogen accumulation. e,
Albumin secretion by CB_iPSC derived hepato-cyte-like cells was
assayed by ELISA. The differentiation medium was changed to fresh
medium 24 h before the assay. The concentration of the ALB secreted
from 30 k iPSC_derived hepatocyte-like cells in 200 ul of media was
measured on differentiation Day 16. Error bars represent the standard
deviation of the mean (N=2)
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Generation of iPSC colonies that carry gene rearrange-
ments could be avoided by selectively expanding and using
non-T, non-B cells for reprogramming. To the best of our
knowledge, the present study is the first to examine the cell
expression pattern of CD13 and CD71 during cell expansion
and after cellular reprogramming. Our protocol is shown to be
robust and much faster than a previous report that showed a
14-days cell expansion was needed to expand erythroblast for
gene-rearrangement-free iPSC generation [25]. We were able
to selectively expand the CD13+ and CD71+ progenitors
using a brief 4-day cell expansion before reprogramming, pro-
viding cell materials to generate iPSC lines without gene re-
arrangements (Fig. 3). In this study, we applied a traditional
PCR assay to detect the gene rearrangement, while in an au-
tomated cell line production scenario, a high-throughput
screening method like Illumnia MiSeq could be used to verify
gene rearrangement status. The medium recipe could be opti-
mized further if a unique cell population is desired by
adjusting the cytokines or depleting any unwanted cell popu-
lation (Fig. 7).
Once the blood reprograms into iPSC cells, colonies could
be manually picked and expanded for further characterization.
Another option is to purify the iPSC via positive selection
(i.e., using anti-TRA-1-60 that specifically binds to iPSC) or
negative depletion. Using FACS analysis, we found those un-
reprogrammed cells in the bulk population are mainly CD13+
and CD71+ cells, thus depletion of CD13+ and CD71+ cells
may be used to achieve a purer iPSC population, offering an
adaptable method to automated cell production systems. The
disadvantage of this strategy is that the iPSCs are from a bulk
population and not a single colony. However, colonies could
be picked manually at any stage after bulk purification if
desired.
In summary, our study allows reprogramming of the most
readily available blood cells and provides a protocol to access
samples stored at blood banks, enabling the blood collection
from pediatric and other populations that cannot easily pro-
vide much peripheral blood or a skin biopsy. The iPSC de-
rived from such blood samples could provide unlimited cell
sources to retrospectively screen for genetic factors, to study
molecular mechanisms underlying blood disorders or other
diseases, to derive the other functional differentiated cells for
drug screening and disease modeling, and could even poten-
tially used for cell therapy.
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